Back to search

Article

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

2023-09-19

Abstract excerpt

<h4>Background: </h4> The introduction of anti-PD-1 antibody has greatly improved the clinical outcomes of patients with non-small cell lung cancer(NSCLC). Here we retrospectively analyzed the efficacy of PD-1 antibody-based therapy in patients with locally advanced un-operable or metastatic NSCLC patients and report an association between peripheral blood biomarkers with clinical response in these patients. Metho...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
19b6d670-8e33-568c-a5dd-60033a3ce9b0
DOI
10.21203/rs.3.rs-3352679/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatmentDOI 10.21203/rs.3.rs-3352679/v1
Characteristics and Hematological Indicators Predictors of Immunotherapy Response in Advanced Non-Small Cell Lung CancerSemantic proximity
Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung CancerSemantic proximity
Effect of PD-1 inhibitor combined with chemotherapy on cytokines and immune cell function in patients with advanced lung cancerSemantic proximity
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity
Prognostic significance of the peripheral blood CD4/CD8 ratio in lung cancer patients: A meta-analysisSemantic proximity
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingSemantic proximity
High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.Semantic proximity
Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity
A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.Semantic proximity
PD-L1 status on Circulating Tumor Cells: A Promising Predictor in Advanced Lung Cancer with PD-1/PD-L1 immunotherapiesSemantic proximity
Real-world Data Analysis of Immunotherapy in Advanced Lung CancerSemantic proximity
Periphery TH/TS ratio and TP53 mutation predict the efficacy of ICI-based therapy in advanced non-small cell lung cancer with high PD-L1 expressionSemantic proximity
Select a neighboring publication to make it the new centre.